Japan’s Medical Insurance Agency Approves NHI Listing For Pfizer’s Macugen, Novartis’ Simulect, Merck Serono's Erbitux Among Others
This article was originally published in PharmAsia News
Executive Summary
Japan's Central Social Insurance Medical Council (Chuikyo) approved Aug. 27 11 drugs to be NHI listed. The drugs priced based on similar drugs include Astellas's Irribow (ramosetron) to treat male irritable bowel syndrome, Pfizer's Macugen (pegaptanib) to treat age-related macular degeneration, Taiho Pharmaceutical's Zosyn (piperacillin/tazobactam), Schering Plough's Nasonex (mometasone furoate), and Galderma's Differin Gel (adapalene). The drugs priced based on a cost accounting system include Pfizer's Mycobutin (rifabutin), Merck Serono's colon cancer drug Erbitux (cetuximab) and Genzyme Japan's Thymoglobulin to treat acute rejection of transplants. Additional drugs to be listed include Astellas' Prograf (tacrolimus) and Novartis' Simulect Pediatric (basiliximab). (Click here for more - Japanese language
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.